SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is experiencing a sharp sell-off as investors react to back-to-back adverse court rulings regarding the platform's impact on young users, fueling fears that these cases could set a precedent for thousands of future lawsuits. The community is deeply polarized, with some bulls viewing the dip as an overreaction and a buying opportunity, while others are panic-selling, citing concerns over long-term legal liabilities, heavy AI spending, and broader market instability.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is trending as the community highlights its strategic role in bridging traditional finance and blockchain, particularly through its high-profile partnership with Franklin Templeton to tokenize ETFs. Investors remain highly focused on its long-term potential as a leader in real-world assets, though discussions reflect ongoing tension between the project's institutional momentum and concerns over token dilution from upcoming supply unlocks.

Robinhood Ventures Fund I invest in companies located in the United States. The fund focuses on a broad range of sectors and industries. It provides financing for early stage transactions.

Robinhood Ventures Fund I - Common shares of beneficial interest

The community is actively discussing the Robinhood Ventures Fund I, with many participants speculating on its potential to replicate the rapid growth seen in similar venture funds. Traders are closely monitoring the fund's current holdings and the potential for future high-profile acquisitions to drive significant price appreciation, despite concerns regarding the fund's expense ratio and the transparency of its valuation.

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Kyverna Therapeutics is capturing market attention as institutional investors and the community closely track its progress in the CAR-T autoimmune space, specifically regarding the upcoming BLA submission and Phase 3 registrational trials for miv-cel. Discussion is fueled by strong insider confidence, robust institutional ownership, and anticipation of data readouts from its pipeline targeting conditions like Stiff Person Syndrome and Myasthenia Gravis.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiak Sciences is trending as shares surge on the back of positive Phase 3 clinical trial results for its Zenkuda eye treatment. The community is actively debating the stock's potential for further upside against the risk of future capital raises and the company's past volatility.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Carnival Corp is facing significant volatility as investors weigh the impact of rising oil prices and geopolitical tensions in the Middle East on cruise operations. While the community is actively debating the stock's sensitivity to fuel costs and broader travel sentiment, many shareholders argue that current share price weakness is an overreaction given the company's strong bookings, record occupancy, and limited direct exposure to the conflict region.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending amid high-stakes volatility as market participants react to shifting signals regarding U.S. military posture in the Middle East and the company's internal fiscal performance. Community discourse is heavily polarized, with critics pointing to mounting losses and geopolitical instability, while supporters maintain a focus on the platform's role in the broader media landscape and political developments.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is trending as investors weigh its robust growth and global expansion plans against concerns over its premium valuation and recent performance shifts in the fast-casual sector. The community is actively debating the sustainability of its store count growth and the impact of its share repurchase programs amidst a broader, often volatile, consumer discretionary environment.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is trending as investors aggressively hedge against market volatility driven by Middle East geopolitical tensions and concerns over potential inflation. Traders are actively debating the sustainability of the current market rally, with many utilizing the inverse fund to hedge their portfolios as they monitor key technical levels and signals of a broader market correction.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is trending as investors weigh the impact of the company's decision to delist from the TSX to focus exclusively on Nasdaq, a move aimed at streamlining trading and improving institutional liquidity. While some in the community see the delisting as a bullish step to reduce arbitrage pressure, sentiment remains deeply polarized as shareholders actively debate the lack of official updates regarding the Helios data center and the potential for a business split to unlock value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hims & Hers Expands Access To Novo Nordisk's FDA-Approved GLP-1 Medications, Including Wegovy Pill

(RTTNews) - Hims & Hers Health Inc. (HIMS) announced that a wide range of Novo Nordisk's FDA-approved GLP-1 medications are now available to eligible customers. This includes the Wegovy pill, the...

Hims & Hers shifts business model after Novo deal

Hims & Hers (HIMS) has taken a beating, with the stock down roughly 70% from its $70 peak and now trading below $21 per share.But the story's changing.After the company's Novo Nordisk (NVO) deal and...

<ul class="summary-bullets"><li>Earlier on Thursday, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735.&nbsp;</li><li>Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.</li><li>Viking CEO Brian Lian said earlier this month that the company will have four late-stage trials by the end of 2026.</li></ul>Shares of Viking Therapeutics Inc. (VKTX) closed 3% higher on Thursday amid speculation for a buyout, and an eventual approval from the U.S. Food and Drug Administration for its experimental obesity drug dubbed the “Ozempic killer.”A Stocktwits user recommended holding the stock, opining that it would remain “slow and steady” until FDA approval.<stembedurl>https://stocktwits.com/GREENCANDLELOVER/message/648672982</stembedurl>Another speculated a “big buyout" for the company.<stembedurl>https://www.stocktwits.com/timfris/message/648671668</stembedurl>Another user highlighted that the company’s obesity asset can dethrone Eli Lilly and Co.’s (LLY) supremacy in the obesity drug segment.<stembedurl>https://www.stocktwits.com/TrustButVerifi/message/648663298</stembedurl>Yet another user called the company’s obesity drug the “Ozempic killer.”<stembedurl>https://www.stocktwits.com/MetricWhale/message/648678023</stembedurl>Overall, retail sentiment around the stock improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to 'normal' levels.<h2 class="st-heading-2">Viking Completes Trial Enrollment</h2>Earlier on Thursday, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss. The trial enrolled about 1,000 patients with type 2 diabetes and who have obesity or who are overweight, the company said. The primary endpoint of the study is the percent change in body weight from baseline after 78 weeks of treatment for participants receiving VK2735 as compared to placebo. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.The dual agonist VK2735 is being developed in both oral and subcutaneous formulations. Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.<h2 class="st-heading-2">Company Stays Bullish On Pipeline</h2>Viking CEO Brian Lian said earlier this month that the company will have four late-stage trials by the end of 2026.“2025 was a big year for us. 2026 is gonna be a big year as well,” Lian said at the Leerink Global Healthcare Conference.The CEO also expressed optimism that weight loss for the subcutaneous VK2735 trials will probably be a “little better than a GLP-1 monoagonist” though he couldn't predict its impact in comparison to other "polyagonists." While Novo Nordisk’s popular weight loss drug Wegovy is a single-agonist drug, Eli Lilly and Company’s Zepbound is a dual agonist.Viking is also looking to file an application to start trials for a novel amylin agonist this quarter, as it seeks to expand its obesity portfolio. Amylin agonists are a class of medication that mimic the hormone amylin, which is co-secreted with insulin by pancreatic -cells to manage glucose levels and appetite.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has gained more than 30% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-teases-three-row-tesla-suv-but-fails-to-ease-delivery-growth-fears/cZ3sEBvRIlE">Elon Musk Teases Three-Row Tesla SUV But Fails To Ease Delivery Growth Fears</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Stock Jumps As Retail Traders Pile Into Obesity Pipeline Bets

A Stocktwits user recommended holding the stock, opining that the stock be “slow and steady” until FDA approval for the company’s experimental obesity drug VK2735. 

Equity

A Stocktwits user recommended holding the stock, opining that the stock be “slow and steady” until FDA approval for the company’s experimental obesity drug VK2735. 


Best Pharmaceutical Stocks To Watch Today - March 26th

Eli Lilly and Company, Terns Pharmaceuticals, and Novo Nordisk A/S are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription drugs and re...

Top Medical Stocks To Follow Now - March 26th

Eli Lilly and Company, UnitedHealth Group, Terns Pharmaceuticals, Johnson & Johnson, Novo Nordisk A/S, Cencora, and Boston Scientific are the seven Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies that develop, manu...

What's Happening With Novo Nordisk Stock Today?

Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA approved GLP 1 medications, including...

<ul class="summary-bullets"><li>Wegovy will be initially available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg injection doses, with a higher 7.2 mg dose to be available later, HIMS said.</li><li>Ozempic injection pens will be available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses.</li><li>HIMS will also introduce a weight-loss membership starting at $39 for the first month, then $149 per month thereafter.</li></ul>Hims &amp; Hers Health Inc (HIMS) grabbed retail attention on Thursday after launching a broad lineup of Novo Nordisk GLP-1 medications on its platform, including the FDA-approved Wegovy pill. The rollout comes just weeks after Novo dropped its patent infringement lawsuit against Hims related to its blockbuster weight-loss drugs.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> was down more than 3%, while <a href="https://stocktwits.com/symbol/NVO">NVO shares</a> climbed nearly 2% higher at the time of writing.<h2 class="st-heading-2">Wegovy To Be Available In Several Doses</h2>HIMS said that eligible patients will have access to multiple treatment options, including Wegovy in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg injection doses, and 1.5 mg, 4 mg, 9 mg, and 25 mg pill forms. A 7.2 mg injection will be available later, the company said.Ozempic injection pens will be available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses for the management of Type 2 diabetes. It has not been approved by the FDA for weight loss.HIMS is introducing a new&nbsp;weight-loss&nbsp;membership that provides comprehensive support, including 24/7 access to healthcare providers, personalized nutrition guidance, regular check-ins, and a peer support community. Membership will start at $39 for the first month, followed by $149 per month thereafter.<h2 class="st-heading-2">Legal Battle Over Compounded Drugs</h2>Last month, Novo Nordisk filed a patent infringement lawsuit against Hims &amp; Hers after the telehealth company introduced a low-cost, compounded version of the Wegovy pill for $49 per month, claiming it contained the same active ingredient as the branded drug. Novo argued that the products violated its patents and misled consumers about safety and effectiveness, prompting the FDA to warn about the use of GLP-1 ingredients in unapproved compounded drugs.However, Novo Nordisk <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk">dropped</a> the lawsuit earlier this month and instead formed a partnership with Hims &amp; Hers, allowing the company to offer FDA-approved versions of Wegovy and Ozempic at more affordable self-pay prices. Hims &amp; Hers also announced it would stop marketing compounded GLP-1 drugs and transition existing patients to FDA-approved treatments.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for both HIMS and NVO remained in the ‘bearish’ territory over the past 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/HIMS_jpg_50a2aae200.webp" alt="HIMS.jpg" width="855" height="94"><figcaption>HIMS' Sentiment Meter and Message Volumes on March 26, 2026 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/NVO_jpg_c11986072f.webp" alt="NVO.jpg" width="862" height="102"><figcaption>NVO's Sentiment Meter and Message Volumes on March 26, 2026 | Source: Stocktwits</figcaption></figure>One user said they were going long after the news came out.<stembedurl>https://stocktwits.com/turnaroundtuesdays01/message/648651986</stembedurl>Year-to-date, HIMS stock has declined by about 37%, while NVO stock has fallen by about 29%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-anktiva-trial-update-bladder-cancer-phase-2-idmc/cZ3rwRfRIjw">ImmunityBio Says Phase 2 Bladder Cancer Trial Has ‘Statistical Power’ – Anktiva-BCG Advances Toward Filing</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS). (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock In Spotlight After Hims & Hers Adds Novo’s GLP-1 Treatments To Its Platform

Eligible patients will be able to access multiple treatment options, including Wegovy in several injection doses and pill forms, as well as Ozempic injection pens.

ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms

Altimmune heads into a pivotal 2026 MASH race, betting its dual agonist pemvidutide can stand out in a crowded field as key catalysts and risks converge.

Wolfe Research Begins Coverage on Novo Nordisk A/S (NYSE:NVO)

Wolfe Research started coverage on shares of Novo Nordisk A/S in a research note on Thursday. They issued a "peer perform" rating for the company...

Altimmune Stock: Neutral Outlook With Big 2026 Catalysts

Altimmune heads into 2026 with high-stakes catalysts as pemvidutide drives its pipeline, but funding needs and dilution risk loom alongside key clinical readouts.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Alphabet $GOOGL

Robinhood $HOOD

Rocket Lab $RKLB

Sandisk $SNDK

The ticker that owned the conversation. This award honors the stock that defined the market narrative through engagement, price action, and cultural presence on the boards.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$0.91	--	--	N/A
Q4 '25	$0.93	$0.95	2.82%	BEAT
Q3 '25	$0.75	$0.69	-7.91%	MISSED
Q2 '25	$0.92	$0.93	1.42%	BEAT
Q1 '25	$0.91	$0.99	9.16%	BEAT

NVO
Novo Nordisk A/S

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest NVO News

NVONovo Nordisk A/S